natgillin/translations-raw huggingface dataset:
<400> 142 gtctttctag aagatgggcg cggtg 25 A method of producing a library of eukaryotic cell clones containing DNA encoding a diverse repertoire of binders that recognise targets, comprising providing donor DNA molecules encoding the binders, and eukaryotic cells, wherein the binders are antibodies, proteins or peptides, introducing the donor DNA into the cells and providing a site-specific nuclease within the cells, wherein the nuclease cleaves a recognition sequence in cellular DNA to create an integration site at which the donor DNA becomes integrated into the cellular DNA, integration occurring through DNA repair mechanisms endogenous to the cells, thereby creating recombinant cells containing donor DNA integrated in the cellular DNA, and culturing the recombinant cells to produce clones, thereby providing a library of eukaryotic cell clones containing donor DNA encoding the repertoire of binders. 
Postupak za proizvodnju biblioteke klonova eukariotske stanice koja sadrži DNA koja kodira raznovrstan repertoar vezujućih sredstava koja prepoznaju ciljne strukture, naznačen time, da postupak obuhvaća sljedeće: ostvarivanje donorskih DNA molekula koje kodiraju vezujuća sredstva, i eukariotske stanice, pri čemu su vezujuća sredstva protutijela, proteini ili peptidi, uvođenje donorske DNA u stanice i osiguravanje nukleaze specifične za mjesto unutar stanica, gdje nukleaza presjeca sekvencu za prepoznavanje u staničnoj DNA da bi stvorila integracijsko mjesto na kojem donorska DNA postaje integrirana u staničnu DNA, pri čemu se integracija odvija putem endogenih staničnih mehanizama reparacije DNA, čime se stvaraju rekombinantne stanice koje sadrže donorsku DNA integriranu u staničnu DNA, i kultiviranje rekombinantnih stanica radi proizvodnje klonova, te se time osigurava biblioteka klonova eukariotske stanice koja sadrži donorsku DNA koja kodira repertoar vezujućih sredstava.
A compound represented by: or a pharmaceutically acceptable salt and/or a stereoisomer thereof. 
ili njegova farmaceutski prihvatljiva sol, stereoizomer, i/ili N-oksid.
The formulation of any one of claims 1 to 3, wherein the zinc chelator is ethylenediaminetetraacetic acid (EDTA). 
Formulacija prema zahtjevu 5, naznačena time da je kelator cinka etilendiamintetraoctena kiselina (EDTA).
The method of aspect 4, wherein mixing the diluted sample with a mixing apparatus includes disposing the filter bag within the mixing apparatus. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što miješanje razrijeđenog uzorka uređajem za miješanje uključuje stavljanje filtarske vrećice u uređaj za miješanje.
The recombinant RhCMV or HCMV vector of paragraph 2, wherein the human pathogen-specific antigen is isolated from human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV), human cytomegalovirus (HCMV), hepatitis C, papillomavirus, Plasmodium, Kaposi's sarcoma associated herpesvirus, Varicella zoster virus, Ebola virus, Mycobacterium tuberculosis, Chikungunya virus, dengue virus, monkeypox virus, herpes simplex 1, herpes simplex 2, Epstein-Barr virus (EBV), poliovirus, influenza virus or Clostridium tetani. 
Rekombinantni vektor RhCMYV ili HCMV u skladu s patentnim zahtjevom 1, naznačen time što se antigen specifičan za ljudski patogen izolira iz virusa humane imunodeficijencije (HIV), virusa majmunske imunodeficijencije (SIV), ljudskog citomegalovirusa (HCMV), hepatitisa C, papilomavirusa, plazmodija, herpesvirusa povezanog s Kaposijevim sarkomom, virusa varicela-zoster, virusa ebole, bakterije Mycobacterium tuberculosis, virusa Chikungunya, virusa denge, virusa majmunskih boginja, herpes simpleksa 1, herpes simpleksa 2, Epstein-Barrovog virusa (EBV), poliovirusa, virusa influence ili bakterije Clostridium tetani.
The organic extract was dried over anhydrous magnesium sulphate and after filtration the solvent removed at reduced pressure. 
Organski ekstrakt se suši iznad anhidridnog magnezij sulfata i nakon filtriranja otapalo se ukloni uz smanjeni tlak.
transplanting one or more human cells into the mouse; administering a drug candidate to the mouse; and monitoring the human cells in the mouse to determine the therapeutic efficacy of the drug candidate. 
(b) primjeni kandidatnog lijeka na navedenom glodavcu; i (c) praćenju ljudskih stanica u glodavcu kako bi se odredilo terapijsku djelotvornost kandidatnog lijeka.
providing a biphasic mixture comprising the compound of formula (XXIII), an organic boronic acid acceptor, a lower alkanol, a hydrocarbon solvent, and aqueous mineral acid; 
(i) osiguravanje dvofazne smjese koja sadrži spoj formule (XXIII), organski akceptor, organobornu kiselinu, niži alkanol, Cs.g ugljikovodonično otapalo i vodenu otopinu mineralno kiseline;
The method of claim 1 further comprising the step of axially injecting plasma into the FRC from axially mounted plasma guns. 
aksijalno injektiranje plazme u FRC iz aksijalno montiranih plazma pištolja (350);
The compound for use of claim 1, wherein the disease or disorder is multiple myeloma. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak pluća.
The composition of any one of claims 1 to 9, wherein (1) is a compound of the formula: 
0. Kompozicija bilo kojeg patentnog zahtjeva 1 do 9, gdje (1) je spoj formule:
The capsule of claim 12 wherein the filler is one of lactose, cellulose, starch, calcium phosphates, calcium carbonate, sugar, or combinations thereof. 
Kapsula u skladu s patentnim zahtjevom 12, naznačena time što se punilo sastoji od laktoze, celuloze, škroba, kalcijevih fosfata, kalcijeva karbonata, šećera ili kombinacija navedenog.
To further illustrate the invention, without limitation, the following embodiments of R13 are within the scope of the invention, in particular for the compounds as the free base or salt thereof: is hydrogen; 
Kako bi se dalje ilustrirao izum bez da ga se ograniči, slijedeći oblici formule IA su unutar dometa izuma pogotovo glede spojeva kao slobodnih baza i njihovih soli: R'* je vodik
The method as described in claim 2 wherein the pellets are hydrophobic at temperatures below approximately 140° F. 
Postupak kako je opisano u zahtjevu 1 naznačen time da su peleti (66) hidrofobni na temperaturama ispod približno 60C (140"F).
A DOTA-bound anti-P-cadherin antibody, wherein the anti-P-cadherin antibody is a chimeric antibody derived from an antibody defined in claim 12. 
DOTA-vezano anti-P-kadherin antitijelo, naznačeno time, da je anti-P-kadherin antitijelo kimerno antitijelo izvedeno iz antitijela definiranog u skladu s patentnim zahtjevom 12.
Thus the compounds of the invention can be used for direct or indirect therapy of any condition caused or characterised by excess body weight, such as the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea. They may also be used for the treatment of pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension or atherogenic dyslipidaemia (or a combination of two or more of these metabolic risk factors), atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke and microvascular disease. 
(c) uporabu u postupku liječenja stanja uzrokovanih ili karakteriziranih s viškom tjelesne težine, dok je to liječenje i/ili prevencija za sljedeće: pretilost, morbidna pretilost, upala povezana s pretilosti, bolest žučnog mjehura povezana s pretilosti, apneja u spavanju povezana s pretilosti, metabolički sindrom, pred-dijabetes, otpornost na inzulin, netolerancija na glukozu, dijabetes tipa II, dijabetes tipa I, hipertenzija, aterogena dislipidemija, ateroskleroza, arterioskleroza, koronarna srčana bolest, bolest periferne arterije, udar ili mikrovaskularna bolest.
transferring the thus obtained compound of general formula (II), wherein R has the above defined meaning, to a compound of general formula (III), wherein R has the above defined meaning, optionally in form of an acid addition salt, 
HR P20140891 T1 pri čemu R ima gore definirano značenje, opcionalno u obliku kiselo adicijske soli, pri čemu se prijenos provodi (b') podilaženjem spoja opće formule (II) dehidraciji 1 (b") hidrogenaciji tako dobivenog spoja opće formule (VII), pr
The present invention relates to the treatment of withdrawal symptoms. 
Ovaj se izum odnosi na liječenje simptoma ustezanja.
The compound or a salt thereof according to claim 1, wherein the compound is selected from the group consisting of: 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 1, gdje spoj je odabran iz grupe koja se sastoji od:
The audio signal encoding method according to claim 1 or 2, wherein in the initialization step, the internal state of the first encoding means is initialized using the internal state had by the first encoding means when the first encoding means encoded a frame preceding the first frame. 
Postupak kodiranja audio signala u skladu s patentnim zahtjevom 1, naznačen time što unutarnje stanje prvog kodera (13) sadrži sadržaj prilagodljive kodne knjige ili vrijednosti koje su držali elementi za kašnjenje linearnog prediktivnog sinteznog filtera.
A delayed release drug formulation according to any of aspects #2 to #4, wherein said second polymeric material is based on the same polycarboxylic acid polymer as said third polymeric material, said the third polymeric material having a higher degree of neutralisation than the second polymeric material. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od patentnih zahtjeva 1 do 3, pri čemu su drugi i treći polimerni materijal na bazi istog polimera polikarboksilne kiseline s trećim polimernim materijalom koji ima viši stupanj neutralizacije od drugog polimernog materijala.
The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein D is NRb and D1 is a bond. 
Tvar iz patentnog zahtjeva 2, pri čemu je D NRb i D1 je veza.
C—increased or decreased depth of the box 
A - prethodna dubina kutije
For the avoidance of doubt, the formula depicted above and the term 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane is meant to embrace the salts in dissociated, partially dissociated or undissociated form, for example in aqueous solution. 
Kako bi se izbjegle nedoumice, termin 3(R)-(2-hidroksi-2,2-ditien-2-ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo [2.2.2]oktan obuhvaća soli u disociranom, djelomično disociranom ili nedisociranom obliku, na primjer u vodenoj otopini.
the material in the layer is in an effective amount to reduce the leak of the antagonist from the intact pharmaceutical product upon exposure to an environmental fluid, as compared to the pharmaceutical product without the layer. The pharmaceutical product of claim 53, wherein the naltrexone hydrochloride is in an amount of from about 2 mg to about 12 mg. 
Farmaceutski proizvod prema zahtjevu 9, naznačen time da je naltrekson hidroklorid u količini od oko 2 mg do oko 12 mg, od oko 2 mg do oko 8 mg i/ili da čestice naltrekson hidroklorida sadrže više od 90%, poželjno više od 95% hidrofobnog materijala.
The three ether layers were combined, washed with IN HC1 (2 X 100 ml.), washed with water (2 X 200 ml.), dried (MgSO4), treated with activated carbon, filtered, and evaporated under vacuum to yield a solid, which was then crystallized from 200 ml. of hot hexane (36 g., 62% yield, m.p. 107-108°C.). 
Tri eterska sloja se spoje, isperu se sa IN HCI (2 x 200 ml.), isperu se sa vodom (2 x 200 ml.), suši se (MgSO:), tretira se sa aktiviranim ugljenom, filtrira, i ispari u vakuumu tako da se dobiva kruta supstancija, koja se kristalizira iz 200 ml. vrućeg heksana (36 g., 62% prinos, t.t. 107-108*C).
A process to make fusidic acid cream as claimed in any of claims 2 and 4 further wherein a chelating agent is added to the step a of claims 2 and 3, said chelating agent being selected from a group comprising Disodium EDTA and the like, either singly or any combination thereof, to form a proportion from about 0.01% (w/w) to 1% (w/w), preferably 0.5% (w/w), more preferably 0.1% (w/w). 
HR P20130515 T1 Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 2 1 4, naznačen time, da se nadalje agens za keliranje dodaje u stupnju a patentnog zahtjeva 2 1 3, a navedeni se agens za keliranje odabire iz skupine koja sadrži dinatrijevu EDTA 1 slične, ili pojedinačno ili bilo koju njihovu kombinaciju, od oko 0,01% (tež.) do 1% (tež.), prvenstveno 0,5% (tež.), pogodnije 0,1% (tež.).
transmitting said modulated data pseudo-streams through respective transmission channels (Ch#1... 
prijenosa navedenih moduliranih pseudo-tokova podataka preko odgovarajućih prijenosnih kanala (Ch#1...
The immunogenic composition according to claim 29, wherein the M72 related antigen consists of a sequence having at least 90% identity to SEQ ID No: 1. 
Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što se antigen srodan M72 sastoji od slijeda najmanje 90% istovjetnog SEQ ID No: 1.
In other examples, the method also includes cooling the reaction mixture to a temperature of between 5 degrees Celsius and ambient temperature after lowering the pH of the reaction mixture. In other embodiments, methods of forming complexes according to FIG. 
Postupak prema zahtjevu 12 ili zahtjevu 14, naznačen time da dodatno nakon koncentriranja reakcijske smjese, ili nakon snižavanja pH reakcijske smjese sadrži hlađenje reakcijske smjese do temperature od između 5 stupnjeva Celzija i temperature okoline.
discharging precipitated solid crystals of the water-soluble compound from the crystallization vessel and discharging a solution of non-crystallised water-soluble compound in water-solvent mixture from the crystallisation vessel. The process according to claim 6, wherein the alcohol is ethanol or 1-butanol, and the process further comprises: fermenting at least part of the remaining water-soluble compound in the solid extracted biomass and/or of the non-crystallised water-soluble compound discharged from the crystallisation vessel in step (e) into the alcohol to obtain a fermentation broth comprising the alcohol; 
Postupak sukladno Zahtjevu 8 pri čemu je alkohol etanol ili 1-butanol, što je postupak za proizvodnju kristalizanje saharoze i alkohola, koji se nadalje sastoji od sljedećih koraka: f) fermentiranje najmanje dijela preostale saharoze u čvrstu izdvojenu biomasu i/ili nekristaliziranu saharozu ispuštenu iz posude za kristalizaciju u koraku e) u alkohol kako bi postigli fermentacijski spoj koji sadrži alkohol: 2) odvajanje barem dijela alkohola dobivenog fermentacijom u koraku f) iz spoja kako bi dobili alkoholni proizvod.
N-heterocyclic substances that are particularly effective in protecting light induced flavour changes are pyrazine derivatives according to formula (I): 
N-heterocikličke tvari koje su naročito djelotvorne za zaštitu od promjena arome induciranih svjetlom su derivati pirazina prema formuli (I):
A process for preparing a compound according to formula (1), or salt thereof, wherein R1 is hydrogen or a nitrogen protecting group, comprising the following steps: 
Postupak za proizvodnju spoja u skladu sa sljedećom formulom (1) ili njegove soli:
UV visualization at 220 nm 
UV vizualizacija na 220 nm
As SDS can be toxic to cells, it is removed from the solubilised IL-2. 
Budući da SDS može biti toksičan za stanice, on se odstranjuje iz otopljenog IL-2.
be incorporated as a flexibilizer in the thermoset coating. 
može se ugraditi u termoreaktivan premaz kao omekšivač.
an alkali metal or alkaline earth metal hydroxide, carbonate, bicarbonate, phosphate, or alkoxide, or ammonium hydroxide; or an organic amine base such as tetramethylguanidine, DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), and the like] in a suitable solvent (e.g. 
hidroksid alkalnog ili zemnoalkalnog metala, karbonat, bikarbonat, fosfat ili alkoksid ili amonijev hidroksid, ili anorganska amino baza kao što je tetrametilgvanidin, DBU (1,8-diazabiciklo[5.4.0]undek-7-en), i slično | u prikladnom otapalu (na pr.
The installation according to claim 1, wherein the installation forms part of the deluge fire extinguishing system or is permanently installed thereon, therein, or in fluid connection therewith. A method of passing smoke and/or mist through a network of conduits of a deluge fire extinguishing system for testing openness of the deluge fire extinguishing system. 
Instalacija (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu instalacija (1) formira dio otvorenog, deluge (gašenje vodom i/ili pjenom) sustava za gašenje požara ili je trajno instalirana na isti, u isti ili u fluidnoj povezanosti s istim.
The method according to claim 5, wherein the crystallization process is carried out at a temperature in the range of 30°C to 60°C or 60°C to 100°C. 
Metoda u skladu sa patentnim zahtjevom 2, gdje je process kristalizacije izveden na temperaturi u opsegu od 30°C do 60°C ili 60°C do 100°C.
represents an optionally substituted C1-6 alkylene group, an optionally substituted C2-6 alkenylene group or an optionally substituted C2-6 alkynylene group; 
supstituenti za C1-6 alkil skupinu, C2-6 alkenilna grupa i C2-6 alkinil skupinu od R5 su jedna ili više skupina odabranih iz skupine supstituenata A;
after SDS addition but before diafiltration) by gel filtration. 
nakon dodavanja SDS, ali prije diafiltracije) pomoću gel filtracije.
Use according to any of the claims 1-7, wherein the substituted trisaccharide core is derived from raffinose, melezitose or maltotriose and wherein the trisaccharide derivate is fully substituted with identical fatty acid ester groups per substituted trisaccharide. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačena time što se supstituiranu trisaharidnu jezgru izvodi iz rafinoze, melezitoze ili maltotrioze, te što je trisaharidni derivat posve supstituiran s istovjetnim esterskim skupinama masnih kiselina po supstituiranom trisaharidu.
The process of claim 14, wherein in step a) the carob pulp is extracted with water. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se u koraku a) pulpa rogača ekstrahira vodom.
General Synthetic Scheme for Quinoxalinones where Y= NHCO 
Opća sintetska shema za kinoksalinone gdje je Y= NHCO
A printed transfer medium for printing articles, in particular textiles, wherein sublimable pigments are applied to the front side of the transfer medium according to claim 13. 
Tiskani medij za prijenos za tiskanje na predmete, naročito na tekstil, naznačen time što se sublimirajući pigmenti nanose na prednju stranu medija za prijenos prema patentnom zahtjevu 10.
The salt of Claim 4 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 169.1, 120.8, and 46.5 ppm. 
Sol iz Zahtjeva 4, naznačena time, da spektar nuklearne rezonance krutog ugljika-13 CPMAS pokazuje signale na 169.1, 120.8, i 46.5 ppm
The resin was filtered, the solvent was evaporated off and the residue was dissolved in water and ethyl acetate. 
Smola je filtrirana, otapalo je upareno a ostatak je otopljen u vodi i etil-acetatu, Vodena faza je odijeljena i hiofilizirana.
A combination according to claim 1 wherein the anti-alpha-4 integrin antibody is a monoclonal antibody. 
Kombinacija u skladu sa zahtjevom 1, naznačena time, da anti-alfa-4 integrin antitijelo je monoklonsko antitijelo.
upon infrared analysis (FT-IR), bands typical of the 1,4-cis and 1,2 units centered at 737 cm−1 and at 911 cm−1, respectively; 
kod infracrvene analize (FT-IR), pojaseve tipične za nizove 1,4-cis 1 1,2, centrirane na 737 cm"! odnosno na911 cm!;
it has an improved homogeneity compared to at least one antibody molecule composition of the same antibody molecule when expressed in the cell line ATCC No. 
- ima poboljšanu homogenost u usporedbi s pripravkom s najmanje jednom molekulom protutijela za istu molekulu protutijela kada se eksprimira u staničnoj liniji ATCC No.
The product was extracted into dichloromethane (2x500ml), washed with 10% sodium bicarbonate solution (500ml), water, brine and dried over Na2SO4. 
Produkt se ekstrahira u diklorometanu (2x500 mL), ispere s 10 % otopinom natrijeva bikarbonata (500 mL), vodom i zasićenom otopinom NaCi, te osuši preko NaSO,.
More particularly, the conjugated nucleic acid molecule has the following formula: 
PATENTNI ZAHTJEVI 1. - Konjugirana molekula nukleinske kiseline, naznačena time što ima sljedeću formulu:
is -H, C1 - C4 alkyl, or substituted 6 - 10 membered aromatic ring substituted methyl; and the substituent of the substituted aromatic ring is -H, halogen or C1-C4 alkyl; 
Ri je -H, Ci - Csalkil, ili supstituirani 6-10-člami aromatski prsten supstituirani metil; te je supstituent supstituiranog aromatskog prstena -H, halogen ili C1 - Ca alkil;
is aryl, wherein said aryl is substituted with 1 substituent R6; 
Rs je aril, gdje je rečeni aril supstituiran s 1 supstituentom Rg;
chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates; 
(ili) kromatografija označava flash kromatografiju na silka-gelu; zankoslojna kromatografija (TLC) je provedena na silikatnim pločicama
Use of a composition according to any one of claims 1 to 36, in the manufacture of a medicament for the treatment of liver fibrosis, atherosclerosis, restenosis, Alzheimer's, Parkinson's, Huntington's chorea, amyotropic lateral sclerosis, spino-cerebellar degeneration, osteoarthritis, rheumatoid arthritis, diabetic retinopathy, anaemia, sickle cell anaemia, thalassaeimia, malaria, trypanosomiasis, helminthiasis, multiple sclerosis, autoimmune diabetes, lupus, atopic dermatitis, asthma, allergic rhinitis, or inflammatory bowel disease. 
Uporaba sastava prema bilo kojem zahtjevu od 1 do 36, naznačena time, da je za proizvodnju lijeka za liječenje jetrene fibroze, ateroskleroze, restenoze, Alzheimer-ove bolesti, Parkinson-ove bolesti, Huntington-ove horeje, amiotropične lateralne skleroze, spino-cerebralne degeneracije, osteoartritisa, reumatoidnog artritisa, dijabetičke HR P20120341 T1 retinopatije, anemije, anemije srpastih stanica, talasemije, malarije, tripanosomijaze, helmintijaze, multiple skleroze, autoimunog dijabetesa, lupusa, atopičnog dermatitisa, astme, alergijskog rinitisa ili upalne bolesti crijeva.
A conjugate according to claim 1 wherein the epitope corresponds to the peptide of SEQ ID NO. 
Konjugat prema zahtjevu 1, naznačen time da epitop odgovara peptidu od SEQ ID NO.
a vacuum sealing layer covering the wound dressing and adapted to retain relative vacuum in the wound contact layer. 
- vakuumski brtveni sloj koji prekriva zavoj za rane i prilagođen da zadrži relativni vakuum u kontaktnom sloju rane.
The method of item 31, wherein the skin disease or disorder is dermatitis, a thermal or chemical burn, a chronic wound, acne, alopecia, other disorders of the hair follicle, epidermolysis bullosa, sunburn, complications of sunburn, a disorder of skin pigmentation, an aging-related skin condition, a post-surgical wound, a scar from a skin injury or burn, psoriasis, a dermatological manifestation of an autoimmune disease or a graft-versus host disease, skin cancer, a disorder involving hyperproliferation of skin cells. 
Farmaceutski pripravak za uporabu prema zahtjevu 31, naznačen time da je kožna bolest ili poremećaj dermatitis, toplinska ili kemijska opeklina, kronična rana, akne, alopecija, ostali poremećaji folikula kose, bulozna epidermoliza, opekline od sunca, komplikacije opeklina od sunca, poremećaj pigmentacije kože, stanje kože povezano sa starenjem, rana poslije operacije, ožiljak od ozljede kože ili opeklina, psorijaza, dermatološka manifestacija autoimune bolesti ili bolest presatka protiv domaćina, rak kože, poremećaj koji uključuje hiperproliferaciju stanica kože.
In one preferred configuration, the portion R1-A-NR2R3 of the compound is represented by the formula R1—X—(CH2)n—NR2R3 wherein X is attached to the group E and is a group CH, and n is 2. 
Spoj prema zahtjevu 10, naznačen time što je dio R'-A-NR/R* spoja predstavljen formulom R'-X(CH>),-NRR? gdje je X spojen na skupinu E i to je skupina CH, in je 2.